Literature DB >> 20002732

Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia.

Tom Møller1, Ove Juul Nielsen, Pernille Welinder, Anne Dünweber, Maiken Hjerming, Claus Moser, Lars Kjeldsen.   

Abstract

Traditionally, patients with acute leukaemia are admitted to hospital during chemotherapy-induced pancytopenia, although a few recent reports have reported the feasibility and safety of outpatient treatment. We have developed an outpatient treatment programme for patients with acute leukaemia incorporating comprehensive patient education for self-care management at home during pancytopenia and involvement of patients in care of their tunnelled central venous catheter (CVC). During neutropenia, patients are treated with prophylactic ciprofloxacine, amoxicillin/clavulanic acid and fluconazole. Herein, we report the results of outpatient treatment of 60 patients with acute leukaemia (54 with acute myeloid leukaemia) followed prospectively in the period from March 2004 to 2007. After induction chemotherapy, outpatient treatment was possible after 48 of 73 induction courses, with no readmission in 19 of these (40%). A total of 129 consolidation courses were administered with outpatient treatment following 116 of these, with no readmission in 69 (59%). The median number of days spent at home with neutrophils below 0.5 x 10(9)/L was 8 d per course following induction and 12 d following consolidation chemotherapy. The predominant cause of readmission was neutropenic fever, in most instances of unknown origin. Coagulase-negative staphylococci and Enterococcus faecium were the most frequently identified bacteria in blood cultures, whereas only four positive blood cultures with multiresistant Escherichia coli were identified in the entire patient cohort, the latter exclusively observed in patients receiving antibiotic prophylaxis. The majority of the patients were able to take care of their CVC including change in dressing and heparin flushing. There were 12 CVC-related infections. There were no treatment-related deaths. We conclude that outpatient treatment of patients with acute leukaemia is feasible and safe.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002732     DOI: 10.1111/j.1600-0609.2009.01397.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  14 in total

Review 1.  Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations.

Authors:  Jennifer E Vaughn; Sarah A Buckley; Roland B Walter
Journal:  Leuk Res       Date:  2016-04-01       Impact factor: 3.156

2.  Multimodal intervention integrated into the clinical management of acute leukemia improves physical function and quality of life during consolidation chemotherapy: a randomized trial 'PACE-AL'.

Authors:  Mary Jarden; Tom Møller; Karl Bang Christensen; Lars Kjeldsen; Henrik Sverre Birgens; Lis Adamsen
Journal:  Haematologica       Date:  2016-04-01       Impact factor: 9.941

3.  Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.

Authors:  Kelly D Getz; Yimei Li; Todd A Alonzo; Matthew Hall; Robert B Gerbing; Lillian Sung; Yuan-Shung Huang; Staci Arnold; Alix E Seif; Tamara P Miller; Rochelle Bagatell; Brian T Fisher; Peter C Adamson; Alan Gamis; Ron Keren; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2015-05-06       Impact factor: 3.167

4.  Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.

Authors:  Jennifer E Vaughn; Megan Othus; Morgan A Powell; Kelda M Gardner; Donelle L Rizzuto; Paul C Hendrie; Pamela S Becker; Paul S Pottinger; Elihu H Estey; Roland B Walter
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

5.  Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.

Authors:  Roland B Walter; Stephanie J Lee; Kelda M Gardner; Xiaoyu Chai; Kathleen Shannon-Dorcy; Frederick R Appelbaum; Elihu H Estey
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

6.  Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  Frances Linzee Mabrey; Kelda M Gardner; Kathleen Shannon Dorcy; Andrea Perdue; Heather A Smith; Alicyn M Davis; Cody Hammer; Donelle Rizzuto; Sunny Jones; Kim Quach; Bart L Scott; Paul C Hendrie; Mary-Elizabeth M Percival; Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Pamela S Becker
Journal:  Blood Adv       Date:  2020-02-25

Review 7.  Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia.

Authors:  Roland B Walter; Lenise R Taylor; Kelda M Gardner; Kathleen Shannon Dorcy; Jennifer E Vaughn; Elihu H Estey
Journal:  Clin Adv Hematol Oncol       Date:  2013

8.  Finding new bearings: a qualitative study on the transition from inpatient to ambulatory care of patients with acute myeloid leukemia.

Authors:  Rinat Nissim; Gary Rodin; Aaron Schimmer; Mark Minden; Anne Rydall; Dora Yuen; Ashley Mischitelle; Peter Fitzgerald; Christopher Lo; Lucia Gagliese; Camilla Zimmermann
Journal:  Support Care Cancer       Date:  2014-04-05       Impact factor: 3.603

9.  Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant E. Coli.

Authors:  Lalit Saini; Coleman Rostein; Eshetu G Atenafu; Joseph M Brandwein
Journal:  BMC Infect Dis       Date:  2013-06-22       Impact factor: 3.090

10.  Outpatient management of intensively treated acute leukemia patients--the patients' perspective.

Authors:  Lene Østergaard Jepsen; Mette Terp Høybye; Dorte Gilså Hansen; Claus Werenberg Marcher; Lone Smidstrup Friis
Journal:  Support Care Cancer       Date:  2015-11-09       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.